Morten Bøttcher

Response to Ferreira et al

Laust D Rasmussen, MD, PhD, Morten Bøttcher, MD, PhD, Simon Winther, MD, PhD, DMSc; Response to Ferreira et al, European Heart Journal - Cardiovascular Ima

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...